Yeungnam Univ J Med.  2019 May;36(2):155-158. 10.12701/yujm.2019.00115.

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor

• Kang MK
• Lee HJ
• Choi JH

• KMID: 2449330
• DOI: http://doi.org/10.12701/yujm.2019.00115

Abstract

Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.

Keyword

Corticosteroids; Drug-induced liver injury; Gastrointestinal stromal tumors; Imatinib mesylate

MeSH Terms

Adrenal Cortex Hormones*
Drug-Induced Liver Injury
Gastrointestinal Stromal Tumors*
Hepatitis*
Humans
Imatinib Mesylate
Steroids
Adrenal Cortex Hormones
Imatinib Mesylate
Steroids

Reference

References

1. Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006; 18:785–7.

2. Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010; 27:768–73.

3. Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer. 2012; 12:186.

4. Yachoui R. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors. Am J Ther. 2014; 21:e148–50.

5. Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006; 91(6 Suppl):ECR27.

6. Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology. 2007; 12:49–53.

7. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004; 9:271–81.

8. Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol. 2014; 20:317–26.

9. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011; 37:75–88.

10. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis. 2017; 21:1–20.

11. Döring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev. 2014; 46:261–82.

12. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002; 1:259–66.

13. Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology. 2017; 66:646–54.

14. Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol. 2016; 29:551–6.